Litcius/Paper detail

miR‐423‐3p activates FAK signaling pathway to drive EMT process and tumor growth in lung adenocarcinoma through targeting CYBRD1

Jun Ma, Wuhao Huang, Chaonan Zhu, Xiaoyan Sun, Qiang Zhang, Lianmin Zhang, Qi Qi, Xiaoming Bai, Yun Feng, Changli Wang

2021Journal of Clinical Laboratory Analysis17 citationsDOIOpen Access PDF

Abstract

BACKGROUND: Lung adenocarcinoma (LUAD) is a malignant tumor with a high fatality rate and poor overall survival, while molecular targets diagnosing and alleviating lung cancer remain inadequate. METHODS: In this article, we highlighted the upregulation of microRNA-423-3p (miR-423-3p) in LUAD, especially in smokers aged over 40, and revealed that the high expression of miR-423-3p was significantly associated with smoker, age, and pathologic stage of LUAD patients. RESULTS: Moreover, overexpressing miR-423-3p could facilitate LUAD cell proliferation, invasion, adhesion, and epithelial-mesenchymal transition (EMT) process, while depleted miR-423-3p caused repressive influence upon it. Mechanically, we identified that miR-423-3p could activate FAK signaling pathway through binding to the 3'-UTR of cytochrome B reductase 1 (CYBRD1). Furthermore, we demonstrated that CYBRD1 was lowly expressed in LUAD, and miR-423-3p overexpression could rescue the impairment of LUAD cell proliferation, invasion, adhesion, and EMT caused by CYBRD1 depletion. Noticeably, miR-423-3p depletion efficiently hindered LUAD tumor growth in vivo. CONCLUSION: Collectively, our findings demonstrated that miR-423-3p/CYBRD1 axis could be regarded as a promising biomarker to alleviate the poor LUAD prognosis.

Topics & Concepts

AdenocarcinomaCancer researchmicroRNAEpithelial–mesenchymal transitionLung cancerDownregulation and upregulationCell growthFocal adhesionLungBiologySignal transductionCancerMedicinePathologyInternal medicineCell biologyGeneBiochemistryCell Adhesion Molecules ResearchHippo pathway signaling and YAP/TAZExtracellular vesicles in disease
miR‐423‐3p activates FAK signaling pathway to drive EMT process and tumor growth in lung adenocarcinoma through targeting CYBRD1 | Litcius